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Outcome of radioactive iodine therapy
in Toxic Nodular Goiter in Pakistan
Tauseef Ahmad1, Adeel Khoja2,
Naveed Haroon Rashid3, Muhammad Areeb Ashfaq4
ABSTRACT
Objective: To determine the outcome of patients receiving radioactive iodine therapy for toxic nodular
goiter coming to Aga Khan University Hospital Karachi.
Methods: A total of 89 patients who visited the outpatient department of Aga Khan University Hospital
from January 2010 to August 2017 were recruited for the study. Toxic nodular goiter was diagnosed on
the basis of having hot nodule on thyroid scan with low TSH and high FT4/T4. Other demographic and
laboratory data were also recorded.
Results: Eighty nine patients with toxic nodular goiter received a dose range from 10 to 30mCi RAI. Six
months after RAI, 36.2% became hypothyroid, 38.5% became euthyroid while 25.3% remained hyperthyroid.
Thyroid outcome at 3 months were correlating with 6 months results.
Conclusion: Radioactive iodine therapy is a safe and effective way of treating toxic nodular goiter which
usually results in cure of hyperthyroidism in majority of patients.
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Toxic thyroid nodule is the second most common
cause of hyperthyroidism after graves’ disease.1 It is
actually a thyroid nodule that becomes autonomous
and results in hyperthyroidism. The autonomic
stimulation is caused by somatic mutation in
thyrotropin or TSH receptors in about 20-80%
of toxic nodules and also in some multi-nodular
goiter.2
Toxic thyroid nodule is different from Graves’
disease as it is not an autoimmune disease and
if treated adequately does not remit.3 American
association of clinical endocrinologist and American
thyroid association have recommended radioactive
iodine (RAI) or surgical intervention to treat toxic
nodular goiter.4 Surgical management although
can cure this problem but has many anesthesia and
surgery related complications.5 RAI is an alternative
to surgery and is effective in treating benign nodular
goiter.6
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Treatment with a single dose of RAI usually
achieve success in 85-100% of patients with toxic
nodular goiter and also shrink the size of the goiter
up to 40%7,8 RAI therapy is dependent on iodine
uptake by the thyroid tissue and its reduce uptake
leads to the treatment being inefficient and more
difficult.9
RAI therapy in toxic thyroid nodules unlike
Graves’ disease, where majority of the patient
becomes hypothyroid, usually result in patient
becoming euthyroid, as the toxic nodule usually
takes majority of radiation. Our study reported the
outcome of RAI on toxic nodular goiter and also
compares the accuracy of thyroid function test
(TFTs) after 3 months of RAI as compared to six
months.

Frequencies with percentages were reported
for all the categorical variables in the dataset.
Variable of Age was converted into categories
to give a meaningful interpretation of the data
with the outcome. Association of Pre RAI TSH
and TSH after six months was done using ChiSquare test statistics (expected cell count was
greater than 5) or Fischer-Exact test statistics
(expected cell count was less than 5). Association
of outcome i.e. TSH after six months with age,
gender and radioactive iodine dose was assessed
through the same statistical tests as mentioned
above. Comparison between three months
and six months TSH values were also assessed
through the same statistical test. All the analysis
was done using Stata version 12.

METHODS

RESULTS

A total of 89 patients with toxic nodular goiter
who visited our outpatient department at Aga Khan
University Hospital from January 2010 to August
2017 were included in our study. Toxic nodular
goiter was diagnosed on the basis of suppressed
TSH, increase serum FT4/T4 levels and hot nodule
on thyroid scan. Patient who were diagnosed to
have thyroiditis or Graves’ disease were excluded
from the study. All patients who had previous
thyroid surgery, neck radiation or had prior RAI
treatment were also excluded from the study. All
those patients who were lost to follow-up were also
omitted from the study.
In all these patients, all the clinical information
like age, sex, height and weight were recorded.
Serum TSH and T4/FT4 levels were measured by
ELISA technique. Patients who had suppressed
TSH levels, increased T4/FT4 levels and had hot
nodule on thyroid scan were labeled to have toxic
nodular goiter. RAI dose was calculated clinically
by consultant nuclear physician on the basis of
size of thyroid nodule, thyroid function test and
radioactive iodine uptake on thyroid scan. At each
follow up visit, data was recorded for serum TSH
andT4/FT4 levels after an interval of three and six
months.
All of our patients were on antithyroid medication
(Carbimazole) prior to RAI as per titration method
according to American Thyroid Association(ATA)
guidelines10 for the last 2-6 months and it was
stopped five days before RAI. The thyroid status
before RAI was also recorded as hypothyroid,
euthyroid or hyperthyroid to access its effect on the
post RAI outcome.

From January 2010 to August 2017, 89 patients
visited Aga Khan University Hospital for toxic
nodular goiter and were given respective radioactive
iodine treatment. A dose of 15 and 20mCi of RAI
was given to majority of the thyroid patients in our
study. At six months follow-up visit, majority of
the patients became Euthyroid (38.2%), followed
by hypothyroid (37.0%), while 24.7% remained
hyperthyroid.
As all of them were on antithyroid drugs before
getting RAI so majority of study participants, who
were in the category of hyperthyroid, converted
to Euthyroid at 6 months after RAI, to be precise
36.5%. Moreover, those falling in the category of
Euthyroid, majority of them either remained in the
same category or shifted to hypothyroid 6 months
after RAI, 43.8% to be precise (equal distribution
among the two categories). For study participants
falling in the category of hypothyroid; majority of
them remained in the category of hypothyroid 6
months after RAI, 50% to be precise. Overall, the
results are not statistically significant since the
p-value is 0.479 (calculated by Fischer Exact Test)
(Table-I).
The variable of age was converted into four
meaningful categories, category one included
study participants from 28 to 40 years, category
two included study participants from 41 to 55
years, category three included study participants
from 56 to 70 years, category four included study
participants from 71 years and above. For those
study participants, falling in the age group of 28
to 40 years, majority of them were hyperthyroid,
38.9% to be precise; study participants falling in the
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Table-I: Comparison of thyroid status before and 6 months after RAI.
Thyroid Status 6 months after RAI

Thyroid Status before RAI
(on antithyroid medication)
No. (%)

Hyperthyroidism
No. (%)

Euthyroidism
No. (%)

Hypothyroidism
No. (%)

Hyperthyroidism

63(70.7)

19 (30.2)

23 (36.5)

21 (33.3)

Euthyroidism

16(17.9)

2 (12.4)

7 (43.8)

7 (43.8)

Hypothyroidism

10(11.2)

1 (10)

4 (40)

5 (50)

Overall p-value of the Table = 0.479 (Fischer Exact Test).
Table-II: Effect of age on thyroid status 6 months after RAI.
Thyroid Status 6 months after RAI
Age (Years)

Hyperthyroidism
No. (%)

Euthyroidism
No. (%)

Hypothyroidism
No. (%)

28-40

7 (38.9)

5 (27.8)

6 (33.3)

41-55

5 (15.6)

13 (40.6)

14 (43.8)

56-70

7 (26)

10 (37)

10 (37)

>71

3 (25)

6 (50)

3 (25)

Overall p-value of the Table = 0.543 (Fischer Exact Test).

age bracket of 41 to 55 years, majority of them were
hypothyroid, 43.8% to be precise; study participants
falling in the age bracket of 56 to 70 years, majority
of them were Euthyroid and hypothyroid (equal
distribution), 37% to be precise; and finally study
participants falling in the age bracket of 71 years
and above, majority of them were Euthyroid, 50%
to be precise. Overall, the results are not statistically
significant since the p-value is 0.543 (calculated by
Fischer Exact Test) (Table-II).
Majority of males were falling in the category
of hypothyroid after 6 months of RAI, 41.7% to
be precise, majority of females were falling in the
category of Euthyroid after 6 months of RAI, 38.8%
to be precise. Overall, the results are not statistically
significant since the p-value is 0.769 (calculated by
Chi-Square Test).
Overall radioactive iodine dose was significantly
associated with the outcome i.e. TFTs after 6
months (p-value of 0.04, calculated by Fischer Exact
Test). When a dose of 10mCi of I131 was given to the
study participants, all remained hyperthyroid after
6 months. When a dose of 15mCi of I131 was given
to the study participants, 50% became hypothyroid
after 6 months, 50.0% to be precise. When a dose of
20mCi of I131 was given to the study participants,
55% became Euthyroid after six months, 55% to be
precise. When a dose of 25mCi of I131 was given to
the study participants, 50% became hypothyroid
Pak J Med Sci
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after 6 months,. Finally, when a dose of 30mCi of
I131 was given to the study participants, 66% became
hypothyroid after six months. (Table-III).
Study participants who were hyperthyroid at
three months, 50% of them remained hyperthyroid
at 6 months after RAI, to be precise 50%. Moreover,
those who were Euthyroid at three months, 70.9%
of them remained Euthyroid 6 months after RAI.
For study participants, who were hypothyroid
at three months, 67.7% remained hypothyroid 6
months after RAI. The test statistics (Fischer Exact
Test) p‑value is < 0.001 and it is highly significant.
This means, that the results of TFTs at three months
do predict the accuracy of the results of TFTs at
six months. The results of all the three different
Table-III: Effect of different doses of RAI
on thyroid outcome after 6 months.
RAI
dose
(mCi)

Thyroid Status after 6 months of RAI
Hyperthyroidism
No. (%)

Euthyroidism
No. (%)

Hypothyroidism
No. (%)

10

2 (0)

0 (0)

0 (100)

15

10 (25)

10 (25)

20 (50)

20

9 (23)

21 (55)

8 (21)

25

1 (16.7)

2 (33.3)

3 (50)

30

0 (0)

1 (33)

2 (66)

Overall p-value of the Table = 0.040 (Fischer Exact Test).
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Table-IV: Comparison between 3rd month and 6th month thyroid function test after RAI.
Thyroid Status after 6 months of RAI

Thyroid Status after 3 months
of RAI

Hyperthyroidism
No. (%)

Euthyroidism
No. (%)

Hypothyroidism
No. (%)

Hyperthyroidism

14 (50)

9 (32.1)

5 (17.9)

Euthyroidism

4 (13.3)

19 (63.3)

7 (23.3)

4 (13)

6 (19.3)

21 (67.7)

Hypothyroidism

Overall p-value of the Table is < 0.001 (Fischer Exact Test).

categories are accurate and we can predict/
conclude that the results at three months and at 6
months are somewhat similar (Table-IV).

hyperthyroid. The dose of RAI used was in the
range from 10 to 30mCi. The literature is widely
diverse with some studies showing 100% cure
rate to 100% failure rate for hyperthyroidism.
(Table-V) Meta-analysis of these studies showed
that the difference of outcome depends not only
on the RAI dose but also on multiple factors like
size of toxic adenoma, radioactive iodine uptake,
hyperthyroidism status prior to RAI therapy and

DISCUSSION
The analyses of our data revealed that
hyperthyroidism was cured in majority of our
patients, with 38.2% being rendered as Euthyroid,
37% became hypothyroid and 24.7% remained

Table-V: Review of literature for RAI on toxic nodular goiter.
Number of
Patients

RAI dose
used in mCi

Blum M
et al., 197513

14

Fontana B
et al.198014

Author

Outcome

Mean year
of follow up

Total years
of follow up

Hyperthyroidism
(%)

Hypothyroidism
(%)

10-15

100

-

6

29

10-40

52

17

10

Eyre-Brook &
Talbot, 198215

37

12-15

32

5.4

6.5

Goldstein &
Hart, 198316

23

15-55

-

36

8.5

4-16.5

Ross DS
et al., 198417

45

5-15

13.3

-

4.9±3.2

0.5-13.5

Hagedus L
et al., 198618

27

7.5

7

-

1

Mariotti S
et al., 198619

138

12.6±4.1

15

4

3.2±2.2

1-11

Ratcliffe GE
et al., 198620

48

10-15

15

-

3.08

2-10

Huysmans DA
et al., 199121

52

20

2

6

10±4

4-17.5

O.Brien T
et al., 199222

23

19.7-100

8.7

3.5

3.8

0.4-16.3

Tzavara I
et al., 200211

126

25-40

0

5.5

5.3±0.4

1-21

Younis J
et al., 201523

60

20-29

0

13.3

5

4-6

Present Study

89

15-20

25.3

36.2
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variability between patients. We used RAI dose
from 10 to 30mCi and our results revealed that
although higher doses are associated with more
hypothyroidism but it was not consistent and we
noticed hyperthyroidism after 6 months even with
25mCi dose of RAI. It clearly reflects that it is not
only the dose of RAI that predict the outcome but
other factors as mentioned above that effect the
individual.
Factors that might have led to these results were
prior anti-thyroid drug treatment because less
hyper toxic nodule has less susceptibility towards
the RAI dose. Toxic nodule usually suppress the
normal thyroid tissue and as they are active, it
subsequently results in uptake of nearly all the RAI
by the toxic nodule while the normal thyroid gland
is saved.11 Thus complete normalization of thyroid
function test prior to RAI may lead to higher
incidence of developing hypothyroidism because
of fading of this protective mechanism and it might
have affected our results as well. It can also lead
to incomplete destruction of toxic nodule that can
result in persistence of hypethryoid state as one of
our patient experienced. Large follicles also lead to
the phenomenon of radio resistance and it is due
to the fact that large nodule with abundant colloid
reduces the effect of beta radiations of RAI.12
Our study is in accordance to other studies that
failed to show any association of age with RAI
outcome.16 Although the subgroup analysis showed
that the young patients up to the age of 40 years
have increased propensity to remain hyperthyroid
but the results were not significant. Gender also did
not show any significant difference either. None
of our patient developed any malignancy in the
post RAI period and it is in agreement with the
previous studies24 but the shorter follow up of our
study precludes us from making any significant
conclusion.
The major reason for the use of RAI now a
days instead of surgery is due to the fact that it is
generally considered a very safe procedure and
the malignant potential of toxic thyroid nodule is
very less.25 The only side effect noted with RAI is
the development of hypothyroidism that is usually
permanent and need lifelong treatment. Previous
long term studies have showed that if a patient
does not develop hypothyroidism in first year, the
chances of development in the subsequent years is
very less.11
Pak J Med Sci
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We also compared post RAI thyroid function
tests after three and six months and the results
showed that the 3rd month TFTs do mirror the true
picture with accuracy (p-value < 0.001) although
the guidelines10 still recommends 6 months TFTs
test as the true reflection of the RAI outcome.
CONCLUSION
In conclusion our study showed that RAI for
toxic nodular goiter is safe and very effective
treatment. It resolves hyperthyroidism in majority
of patients.
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